Inventor · disambiguated record
Matthew H. Porteus
Also filed as: PORTEUS MATTHEW · PORTEUS MATTHEW H · PORTEUS MATTHEW HEBDEN
16 granted patents·28 pending applications·44 citations·filing 2003–2024
90Inventor score
Files withUNIV LELAND STANFORD JUNIOR28VERTEX PHARMA6AUXOLYTIC LTD3BALTIMORE DAVID1CALIFORNIA INST OF TECHN1
Top patents by PatentIndex Score
44 records- 0195US10738305B2Materials and methods for treatment of hemoglobinopathiesVERTEX PHARMA·Filed 2016·Granted Aug 11, 2020·13 cites·14 claims
- 0294US11535846B2Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulationUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Dec 27, 2022·4 cites·30 claims
- 0391US11492646B2Nuclease-mediated genome editing of primary cellsUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Nov 8, 2022·3 cites·30 claims
- 0490US11306309B2Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulationUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Apr 19, 2022·9 cites·37 claims
- 0589US11193141B2Nuclease-mediated genome editing of primary cells and enrichment thereofUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Dec 7, 2021·8 cites·19 claims
- 0689US10006053B2Use of chimeric nucleases to stimulate gene targetingCALIFORNIA INST OF TECHN·Filed 2016·Granted Jun 26, 2018·4 cites·16 claims
- 0786US11634732B2Pharmaceutical compositions comprising gene-corrected primary cellsUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Apr 25, 2023·1 cites·15 claims
- 0884US2024401034A1Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene CorrectionUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 0983US12442016B2Scarless genome editing through two-step homology directed repairUNIV LELAND STANFORD JUNIOR·Filed 2023·Granted Oct 14, 2025·0 cites·14 claims
- 1083US2025215427A1Materials and Methods for Treatment of HemoglobinopathiesVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 1181US11692202B2Scarless genome editing through two-step homology directed repairUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Jul 4, 2023·1 cites·22 claims
- 1279US11851652B2Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBBUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Dec 26, 2023·0 cites·22 claims
- 1375US2025146004A1Materials and Methods for Treatment of Human Genetic Diseases Including HemoglobinopathiesVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 1472US2022204995A1Non-disruptive gene targetingUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 1571US2025171800A1Materials and Methods for Treatment of HemoglobinopathiesVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 1671US2023250423A1Genome editing of human neural stem cells using nucleasesUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 1770US12134767B2Materials and methods for treatment of hemoglobinopathiesVERTEX PHARMA·Filed 2020·Granted Nov 5, 2024·0 cites·19 claims
- 1869US9447434B2Use of chimeric nucleases to stimulate gene targetingBALTIMORE DAVID·Filed 2003·Granted Sep 20, 2016·1 cites·2 claims
- 1966US2021214752A1Non-disruptive gene targetingUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 2066US2025312488A1Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cellsUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 2163US2024382528A1Treatment of polycythemia vera via crispr/aav6 genome editingUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2263US2024409958A1Differential proliferation of human hematopoietic stem and progenitor cells using truncated erythropoietin receptorsUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2362US2025127927A1Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cellsUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2461US2017233765A1Non-disruptive gene targetingUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 2560US2013280222A1Non-disruptive gene targetingUNIV TEXAS·Filed 2013·Application pending·0 cites
- 2659US2023357798A1Gene correction for x-cgd in hematopoietic stem and progenitor cellsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 2758US12129471B2Materials and methods for treatment of human genetic diseases including hemoglobinopathiesVERTEX PHARMA·Filed 2016·Granted Oct 29, 2024·0 cites·14 claims
- 2858US2024093242A1Gene correction for scid-x1 in long-term hematopoietic stem cellsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 2958US2024173355A1Gene correction for rag2 deficiency in human stem cellsUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 3058US2022356450A1Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cellsUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 3158US2025305004A1Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatmentUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 3254US2023265440A1Targeting the human ccr5 locus as a safe harbor for the expression of therapeutic proteinsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3352US2023256026A1Gene editing for the treatment of epidermolysis bullosaUNIV MADRID CARLOS III·Filed 2021·Application pending·0 cites
- 3452US2022145286A1Barcoded clonal tracking of gene targeting in cellsCHAN ZUCKERBERG BIOHUB INC·Filed 2020·Application pending·0 cites
- 3550US2022280571A1Compositions and methods for treating alpha thalassemiaUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 3649US2021386915A1Compositions and methods for airway tissue regenerationUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3748US12043843B2Materials and methods for treatment of hemoglobinopathiesCRISPR THERAPEUTICS AG·Filed 2016·Granted Jul 23, 2024·0 cites·12 claims
- 3847US2023085945A1Orthogonal safety switches to eliminate genetically engineered cellsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3945US2022325301A1Auxotrophic selection methodsAUXOLYTIC LTD·Filed 2020·Application pending·0 cites
- 4044US2017298348A1Genome editing of human neural stem cells using nucleasesUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 4143US11773409B2CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectorsUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Oct 3, 2023·0 cites·19 claims
- 4243US2021052741A1Gene therapy methods and compositions using auxotrophic regulatable cellsAUXOLYTIC LTD·Filed 2020·Application pending·0 cites
- 4342US11903969B2Genome editing of graft-derived T-cells for post-transplant immunotherapyUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Feb 20, 2024·0 cites·19 claims
- 4439US2022290103A1Methods and compositions using auxotrophic regulatable cellsAUXOLYTIC LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew H. Porteus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →